LakeShore Biopharma Co (LakeShore Biopharma Co) Total Liabilities : $144.45 Mil (As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co Total Liabilities?

LakeShore Biopharma Co's Total Liabilities for the quarter that ended in Sep. 2023 was $144.45 Mil.

LakeShore Biopharma Co's quarterly Total Liabilities declined from Sep. 2022 ($356.03 Mil) to Mar. 2023 ($143.86 Mil) but then increased from Mar. 2023 ($143.86 Mil) to Sep. 2023 ($144.45 Mil).

LakeShore Biopharma Co's annual Total Liabilities increased from Mar. 2021 ($257.42 Mil) to Mar. 2022 ($337.41 Mil) but then declined from Mar. 2022 ($337.41 Mil) to Mar. 2023 ($143.86 Mil).

LakeShore Biopharma Co Total Liabilities Historical Data

The historical data trend for LakeShore Biopharma Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co Total Liabilities Chart

LakeShore Biopharma Co Annual Data

Trend

Mar21

Mar22

Mar23

Total Liabilities

257.42

337.41

143.86

LakeShore Biopharma Co Semi-Annual Data
	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Total Liabilities	Get a 7-Day Free Trial			-	337.41	356.03	143.86	144.45

LakeShore Biopharma Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

LakeShore Biopharma Co's Total Liabilities for the fiscal year that ended in Mar. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	95.599	+	(43.556	+	1.275
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	3.426	+	0)
	=	143.86

Total Liabilities	=	Total Assets (A: Mar. 2023 )	-	Total Equity (A: Mar. 2023 )
	=	249.569	-	105.712
	=	143.86

LakeShore Biopharma Co's Total Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	90.864	+	(50.21	+	0.29999999999999
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	3.077	+	0)
	=	144.45

Total Liabilities	=	Total Assets (Q: Sep. 2023 )	-	Total Equity (Q: Sep. 2023 )
	=	220.787	-	76.336
	=	144.45

LakeShore Biopharma Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

LakeShore Biopharma Co (LakeShore Biopharma Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

H6Z:Germany

Address

38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629

Website

https://www.yishengbio.com

YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.